Trial Profile
A Dose Ranging Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) Versus Control in Subjects With ESRD Receiving Chronic Hemodialysis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric pyrophosphate (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors Rockwell Medical Technologies
- 12 Dec 2014 New trial record